Activiomics Ltd.

Investment in Queen Mary, University of London spin-out to fund growth strategy

UCB seeking to understand cell signalling mechanisms of therapeutic antibodies enabling identification of biomarkers

Scientists at Barts and The London School of Medicine and Dentistry at Queen Mary University of London, have developed a novel method of analysing and interpreting cell signalling pathways.